Literature DB >> 23018424

Intravitreal injections: is there benefit for a theatre setting?

Robin G Abell1, Nathan M Kerr, Penelope Allen, Brendan J Vote.   

Abstract

OBJECTIVE: To investigate and compare the rate of endophthalmitis after intravitreal injections performed in an in-office (dedicated procedure room) versus in-theatre setting.
METHODS: A retrospective comparative cohort study was performed of all patients consecutively treated by a single surgeon with intravitreal injection with either ranibizimab or bevacizumab for any recognised clinical indication. All cases received injections between March 2006 and March 2012, during which time all injections were prospectively recorded on an electronic medical record system. A search of the electronic database using a report building system was used to extract the total number of injections into location-specific grouping (ie, in office vs in theatre).
RESULTS: 12 249 injections were performed over a 6-year period. 3376 of these were performed in the in-office procedure room, compared with 8873 in the operating theatre. Of the 3376 injections performed in office, there were four cases of infective endophthalmitis compared with none of the 8873 injections performed in theatre (p=0.006). In-theatre intravitreal injections were associated with a 13-fold lower risk of endophthalmitis compared to in-office injections.
CONCLUSIONS: The theatre environment is a clinically appropriate location for any intravitreal injection procedures and was associated with a significantly lower risk of infective endophthalmitis in this single-surgeon comparative cohort study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23018424     DOI: 10.1136/bjophthalmol-2012-302030

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection.

Authors:  Philip Storey; Michael Dollin; Nadim Rayess; John Pitcher; Sahitya Reddy; James Vander; Jason Hsu; Sunir Garg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-05       Impact factor: 3.117

2.  Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.

Authors:  Stephen G Schwartz; Harry W Flynn
Journal:  Curr Ophthalmol Rep       Date:  2014-03-01

3.  Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.

Authors:  Meidong Zhu; Jamie K Chew; Geoffrey K Broadhead; Kehui Luo; Nichole Joachim; Thomas Hong; Adil Syed; Andrew A Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-09-10       Impact factor: 3.117

Review 4.  Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis.

Authors:  Douglas K Sigford; Shivani Reddy; Christine Mollineaux; Shlomit Schaal
Journal:  Clin Ophthalmol       Date:  2015-05-02

Review 5.  Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review.

Authors:  Rohan Merani; Alex P Hunyor
Journal:  Int J Retina Vitreous       Date:  2015-07-21

6.  Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis.

Authors:  Manuel F Bande; Raquel Mansilla; María P Pata; Maribel Fernández; María José Blanco-Teijeiro; Antonio Piñeiro; Francisco Gómez-Ulla
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

7.  Anterior infectious necrotizing scleritis secondary to Pseudomonas aeruginosa infection following intravitreal ranibizumab injection.

Authors:  Razek Georges Coussa; Susan M Wakil; Hady Saheb; David E Lederer; Karin M Oliver; Devinder P Cheema
Journal:  Am J Ophthalmol Case Rep       Date:  2016-10-29

8.  Intravitreal Injection of Bevacizumab: Review of our previous Experience.

Authors:  Mehrdad Afarid; Ali Sadegi Sarvestani; Feisal Rahat; Ali Azimi
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

Review 9.  Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections.

Authors:  P Et Lau; K S Jenkins; C J Layton
Journal:  J Ophthalmol       Date:  2018-07-24       Impact factor: 1.909

10.  Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait.

Authors:  Vivek B Wani; Jamal Al-Kandari; Khalid Sabti; Faisal Aljassar; Hussain Qali; Niranjan Kumar; Anilkumar Uboweja; Khalid Al-Sabah; Fahad A Diab; Saleh Al-Rashidi
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.